Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03336632
Other study ID # HX-GVHD-1
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2019
Est. completion date March 30, 2021

Study information

Verified date July 2018
Source Sichuan University
Contact Jie Ji, MD
Phone 86-28-85422373
Email jieji@scu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.


Description:

Eligible patients were aged 16 to 65 years, diagnosed with hematologic malignancy, and had a Karnofsky performance score of ≥70% and were candidates for myeloablative HCT. A 8/8 HLA allelic match between the donor and the recipient at HLA-A, HLA-B, HLA-C, and HLA-DRB1 by high-resolution typing was required. The graft source was PBSC.

Patients received a myeloablative conditioning regimen consisting of oral chidamide given twice weekly at a dose of 20 mg from day -7 to 2 weeks post transplantation, intravenous busulfan 3.2 mg/kg from day -6 to -3, intravenous fludarabine 30 mg/m2 and cytarabine 1g/m2 respectively from day -6 to -2. PBSCs were infused on day 0. GVHD prophylaxis was post-transplantation cyclophosphamide (50 mg/kg on day +3, +4) and cyclosporine (started from day +5). In the absence of GVHD, cyclosporine tapering started on day +100 and discontinued on day +180. Minimal residual disease (MRD) was determined by multi-parameter flow cytometry.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date March 30, 2021
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age = 16 years or older, and = 65 years at time of enrollment

2. Signed informed consent

3. Hematologic disorder requiring allogeneic hematopoietic cell transplantation

4. Left ventricular ejection fraction (LVEF) = 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram

5. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted = 50% of predicted values on pulmonary function tests

6. Transaminases (AST, ALT) < 3 times upper limit of normal (ULN) values

7. Creatinine clearance calculated = 50 mL/min

8. Karnofsky Performance Status Score = 60%.

9. Human leukocyte antigen (HLA) matched 8/ (A, B, C, DRB1) related or unrelated donor

Exclusion Criteria:

1. Active infection not controlled with appropriate antimicrobial therapy HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection

2. Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) =4

3. Anti-thymocyte globulin (ATG) as part of the conditioning regimen

4. Pregnancy

5. Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days

6. Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first chidamide treatment

7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Any history of ventricular fibrillation or torsade de pointes; Bradycardia defined as heart rate (HR)< 45 bpm (Patients with pacemakers are eligible if HR = 45 bpm); Screening electrocardiogram (ECG) with a QTcF > 480 msec; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina = 12 months prior to starting study drug; Other clinically significant heart disease (e.g., New York Heart Association (NYHA) class III or IV , uncontrolled hypertension) as per discretion of principal investigator and/or treating physician; Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs listed on Appendix B of study documents that are required for hematopoietic cell transplantation (HCT) patients.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chidamide
20 mg orally, twice weekly from D-7 to D+14
Cyclophosphamide
50 mg/Kg intravenously D+3, +4
cyclosporine A
3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease

Locations

Country Name City State
China West China Hospital of Sichuan University Chengdu Sichuan
China West China Hospital of Sichuan University Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Sichuan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary aGVHD accumulated incidence of aGVHD 100 day after infusion of PBSCs
Secondary GRFS GVHD free, relapse free survival 3 years after recruitment
Secondary DFS Disease free survival 3 years after recruitment
Secondary OS Overall survival 3 years after recruitment
Secondary cGVHD accumulated incidence of cGVHD 2 yeas after infusion of PBSCs
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Recruiting NCT03680677 - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Recruiting NCT05009537 - Optical Genome Mapping in Hematological Malignancies
Not yet recruiting NCT04110925 - Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia N/A
Terminated NCT04638309 - APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) Phase 1
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Completed NCT02103478 - Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Phase 1/Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT02214407 - Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Phase 3
Recruiting NCT05582902 - Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
Not yet recruiting NCT05024877 - Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Phase 2/Phase 3
Completed NCT00321711 - Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Phase 2
Recruiting NCT06156579 - Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML Phase 2
Recruiting NCT05226455 - Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase 1/Phase 2
Completed NCT01690507 - Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML) Phase 1/Phase 2